News | October 24, 2011

American College of Cardiology Launches PINNACLE-AF Outpatient Registry


October 24, 2011 – The American College of Cardiology (ACC) announced it is expanding its outpatient PINNACLE Registry with a new platform focusing on atrial fibrillation (AF), including the next generation of anticoagulants.

 The new platform, PINNACLE-AF, will operate within the existing PINNACLE Registry.  The PINNACLE Registry is the largest cardiovascular outpatient database in the United States and is part of the ACC’s National Cardiovascular Data Registry (NCDR). NCDR is the most comprehensive, outcomes-based cardiovascular patient data registry for quality improvement in the United States.

“The expansion of the PINNACLE Registry is coming at a time when new treatments for atrial fibrillation are coming online,” said Jack Lewin, M.D., CEO of the American College of Cardiology. “In this context of innovation, PINNACLE can provide a means to monitor practice pattern changes over time while we rigorously assess current practice patterns and help providers evaluate and improve adherence to established guidelines and performance measures. The expansion will also provide a deeper data repository for future research and innovation.”

PINNACLE currently has 2.1 million patient records representing valid patient encounters from hundreds of outpatient practices nationwide. Of those patients, over 100,000 have atrial fibrillation. Participation in the registry is free to all cardiology practices.

Atrial fibrillation is a cardiac rhythm disorder in which the upper chambers of the heart, the atria, beat irregularly and out of sync with the two lower chambers. Symptoms include an irregular or rapid heart rate, shortness of breath, and weakness.  While AF itself is not commonly fatal, it often is associated with increased risks of death and stroke. 

For more information: www.PINNACLEregistry.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now